DIRS.INFO The most relevant business & tech news

☆ Moderna CEO: We're preparing our FDA filing for our RSV vaccine
▼ + stars: | 2023-01-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna CEO: We're preparing our FDA filing for our RSV vaccineModerna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's accomplishments in the last few years, insight into the company's RSV vaccine, and more.

☆ Davos 2023: Moderna CEO says he wants to have mRNA factory on every continent
▼ + stars: | 2023-01-18 | by ( ) www.reuters.com time to read: 1 min

Companies Moderna Inc FollowDAVOS, Switzerland, Jan 18 (Reuters) - Moderna (MRNA.O) chief executive Stephane Bancel said he would like to have factories making vaccines based on its messenger RNA technology on every continent as the U.S. company prepares to build four facilities. "We're talking to a couple more countries because I would really like on every continent to have MRNA capacity," he said on a panel at the World Economic Forum annual meeting in Davos. The company is building or planning to build factories in Canada, Australia, Britain and Kenya, he said. Its COVID-19 vaccines are made in the United States and Switzerland. For daily Davos updates in your inbox sign up for the Reuters Daily Briefing hereReporting by Josephine Mason and Natalie Grover; Editing by Alexander SmithOur Standards: The Thomson Reuters Trust Principles.

RSV, which produces symptoms similar to a cold but can be fatal for young children and older adults, causes about 14,000 deaths annually in adults ages 65 and older. Moderna, Pfizer Inc (PFE.N) and GSK Plc (GSK.L) are racing to get their RSV vaccines to market first. Pfizer's RSV vaccine was found to be 66.7% effective against two or more symptoms in late-stage trials. "It's very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines have shown pretty remarkable results as well," Hoge said. The RSV vaccine market could be worth more than $10 billion globally, half of which would come from the United States, according to Cowen analyst Tyler Van Buren.

☆ Goldman Sachs' bad quarter is the result of environmental factors, says Steve Weiss
▼ + stars: | 2023-01-17 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGoldman Sachs' bad quarter is the result of environmental factors, says Steve WeissSteve Weiss, chief investment officer and managing partner of Short Hills Capital Partners LLC, joins 'Closing Bell Overtime' to discuss Goldman Sachs' earnings miss, the environmental factors impacting the company's margins and Moderna's RSV vaccine news.

☆ Stock futures fall as earnings season continues
▼ + stars: | 2023-01-17 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

A trader works on the trading floor at the New York Stock Exchange (NYSE) in New York, August 3, 2022. Shares of Goldman Sachs tumbled —and dragged on the 30-stock index — after the bank posted an earnings miss. Those moves follow earnings results from big banks that suggested diverging paths ahead even for names within the same sector. It's no longer just about the Fed," Young added. Corporate earnings season will continue with earnings from J.B. Hunt Transport Services, Charles Schwab, PNC Financial Services Group and Discover on deck for Wednesday.

☆ Moderna's phase three RSV trial found to be 83.7% effective in older adults
▼ + stars: | 2023-01-17 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna's phase three RSV trial found to be 83.7% effective in older adultsCNBC's Meg Tirrell joins 'Closing Bell' to discuss Moderna's phase three trial results for its RSV vaccine, the decision to submit the vaccine for regulatory review and the competitive landscape for RSV vaccines.

☆ Moderna says RSV vaccine is 84% effective at preventing disease in older adults
▼ + stars: | 2023-01-17 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

Moderna on Tuesday said its vaccine targeting respiratory syncytial virus is effective at preventing disease in older adults. The vaccine was 83.7% effective at preventing lower respiratory tract disease, defined as two or more symptoms, in people ages 60 and older, according to the Boston biotech company. It was 82.4% effective at preventing lower respiratory tract disease with three or more symptoms. Moderna's RSV vaccine uses the same messenger RNA technology as the company's successful Covid shots. Morgan Stanley estimates the market for an adult RSV vaccine is $7 billion to $10 billion.

☆ CDC says it’s ‘very unlikely’ Pfizer booster carries stroke risk for seniors after launching review
▼ + stars: | 2023-01-13 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

A CDC spokesperson said this issue was first detected in late November. By mid-December, the CDC concluded the concern was persisting and launched an investigation into whether seniors are more likely to have a stroke in the first 21 days after receiving the Pfizer booster, the spokesperson said. The VSD monitoring system found that 130 people ages 65 and older had a stroke within 21 days of receiving the Pfizer omicron booster among about 550,000 seniors who received the shot, the CDC spokesperson said. No other surveillance system has detected a similar safety concern for the Pfizer booster so far, according to the CDC. The CDC has not changed its recommendation for the Pfizer omicron shot.

☆ U.S. FDA, CDC see early signal of Pfizer bivalent COVID shot's link to stroke
▼ + stars: | 2023-01-13 | by ( ) www.reuters.com time to read: +2 min

Jan 13 (Reuters) - A safety monitoring system flagged that U.S. drugmaker Pfizer Inc (PFE.N) and German partner BioNTech's updated COVID-19 shot could be linked to a type of brain stroke in older adults, according to preliminary data analyzed by U.S. health authorities. An ischemic stroke, also known as brain ischemia, is caused by blockages in arteries that carry blood to the brain. "Although the totality of the data currently suggests that it is very unlikely that the signal in VSD (Vaccine Safety Datalink) represents a true clinical risk, we believe it is important to share this information with the public," the health authorities said. Pfizer and BioNTech said in a statement that they have been made aware of limited reports of ischemic strokes in people 65 and older following vaccination with their updated shot. This safety concern has not been identified with Moderna's (MRNA.O) bivalent shot and both the CDC and FDA continue to recommend that everyone aged 6 months and older stay up-to-date with their COVID-19 vaccination.

A key adviser to the Food and Drug Administration's vaccine panel is questioning whether more Covid booster shots are necessary for healthy, younger people. The FDA later backed the vaccine panel, authorizing a new formulation of the booster shots. “The people who are talking about why young people need it are missing the point,” he said, referring to the booster. Levy, the director of the Precision Vaccines Program at Boston Children’s Hospital, continues to encourage Covid boosters for everyone who is eligible. Relatively few people in the U.S. have had updated boosters.

☆ Here are Wednesday's biggest analyst calls: Apple, Tesla, Netflix, Amazon, Salesforce, Levi's & more
▼ + stars: | 2023-01-11 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Bank of America downgrades Coinbase to underperform from neutral Bank of America said it sees too many headwinds for the crypto exchange. Goldman Sachs downgrades Jefferies to neutral from buy Goldman said it sees a "backlog decline" for the investment bank company. Bank of America upgrades Toll Brothers and Pulte Group to buy from neutral Bank of America upgraded several homebuilders, citing compelling valuations. "We upgrade PulteGroup to Buy (from Neutral), Toll Brothers to Buy (from Neutral), and Lennar to Neutral (from Underperform). Bank of America upgrades Dow to neutral from underperform Bank of America said it's taking a more "offensive" approach to the stock.

☆ Sen. Sanders asks Moderna not to hike COVID vaccine price
▼ + stars: | 2023-01-10 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

[1/5] Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Mississippi, U.S. December 20, 2020. Senator Bernie Sanders sent Moderna Inc (MRNA.O) a letter this week asking the drug company to halt planned U.S. price increases on its COVID-19 vaccine, saying price hikes could make the shot unaffordable for millions of Americans. Sanders said in his letter that raising prices would be particularly egregious after the U.S. government provided around $1.7 billion to fund development of the vaccine. The Vermont senator has railed against high drug prices and backed Medicare-for-all, and his chairmanship of the HELP committee could put drug companies in his crosshairs. Moderna's COVID-19 vaccine sales were around $18.4 billion in 2022.

☆ Mainland Chinese citizens are eager to travel — for the West's mRNA Covid vaccines
▼ + stars: | 2023-01-10 | by ( Lee Ying Shan | ) www.cnbc.com time to read: +4 min

Passengers prepare to enter Shenzhen through the Lok Ma Chau Spur Line Control Point on the first day of the resumption of normal travel between Hong Kong and mainland China on Jan. 8, 2023 in Hong Kong. Analysts expect that the list of destinations for vaccine tourism will grow. 'Natural first destination': Hong Kong"I believe that the natural first destination of the Chinese vaccine tourism is Hong Kong. "It's been long since I went to Hong Kong. But Hong Kong won't provide free Covid vaccinations to short-term travelers.

☆ Sen. Bernie Sanders urges Moderna not to hike price of Covid-19 vaccines
▼ + stars: | 2023-01-10 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Sen. Bernie Sanders on Tuesday urged Moderna not to quadruple the price of its Covid-19 vaccine once distribution of the shots moves to the commercial market. In a letter to Moderna CEO Stephane Bancel, Sanders called the price increase "outrageous." Private health insurance premiums would also rise as a consequence of a vaccine price hike , Sanders wrote. Pfizer is also considering raising the price of its Covid vaccine to $110 to $130 per dose. Moderna's Covid vaccine is the company's only commercially available product.

☆ Moderna Considers Price of $110-$130 for Covid-19 Vaccine
▼ + stars: | 2023-01-09 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

Moderna Inc. said it is considering pricing its Covid-19 vaccine in a range of $110 to $130 per dose in the U.S. when it shifts from government contracting to commercial distribution of the shots. The range is similar to the one Pfizer Inc. said in October it was considering for the Covid-19 vaccine it developed with BioNTech SE .

☆ Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
▼ + stars: | 2023-01-09 | by ( ) www.reuters.com time to read: +1 min

Jan 9 (Reuters) - Ocugen Inc (OCGN.O) said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States. The vaccine, sold under brand name Covaxin, showed an immune response in individuals who had not received a COVID vaccine previously as well as those vaccinated with mRNA vaccines by Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O), meeting its main goals, Ocugen said. Ocugen did not provide details about its submission to the U.S. FDA for the vaccine. The company is responsible for conducting trials and commercialization of the shot in the United States under a partnership with Bharat Biotech. The U.S. Food and Drug Administration had also paused trials of the shot after WHO's inspection of Bharat Biotech's facility.

☆ The billionaire CEO of a top biotech VC firm details how a new type of AI could transform how we test and discover treatments
▼ + stars: | 2023-01-09 | by ( Sarah Braner | ) www.businessinsider.com time to read: +3 min

Afeyan is the CEO and founder of Flagship Pioneering, the venture firm behind Moderna. Flagship has in its portfolio multiple companies using AI in areas like drug discovery and testing. The Flagship method for company building starts with a vague "what if" question, and if the idea survives testing, it's unveiled to the public, Afeyan told Insider in 2021. Afeyan isn't alone in predicting that generative AI is gearing up to play a bigger role in healthcare. Morgan Cheatham, a vice president at Bessemer Venture Partners, told Insider he predicted generative AI would result in more than $1 trillion in value for the healthcare industry by 2040.

☆ Watch CNBC's full interview with Moderna CEO Stephane Bancel
▼ + stars: | 2023-01-09 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Moderna CEO Stephane BancelCNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023.

☆ We are in discussion with the Chinese government over the Covid vaccine, says Moderna CEO
▼ + stars: | 2023-01-09 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe are in discussion with the Chinese government over the Covid vaccine, says Moderna CEOCNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023.

☆ Chinese-made mRNA vaccine starts trial production
▼ + stars: | 2023-01-07 | by ( ) www.reuters.com time to read: +1 min

SHANGHAI, Jan 7 (Reuters) - China's CanSino Biologics Inc (6185.HK) has entered "test production phase" for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late on Thursday. The CanSino booster vaccine is one of China's first home-grown potential vaccines based on mRNA technology similar to that employed in vaccines produced internationally by Pfizer-BioNTech and Moderna. On Thursday, CanSino also reported "positive" interim data from a mid-stage clinical trial in a filing to the Hong Kong stock exchange. According to CanSino, the first phase of its mRNA vaccine production could produce 100 million doses. Reporting by Casey Hall; Editing by Jacqueline WongOur Standards: The Thomson Reuters Trust Principles.

☆ Here are Friday's biggest analyst calls of the day: Apple, Amazon, Uber, Nike, Boeing, Netflix & more
▼ + stars: | 2023-01-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +10 min

Baird names Boeing a top 2023 pick Baird named Boeing as a top idea this year and says it sees a recovery in aerospace. UBS names Target a top pick in 2023 UBS says it sees Target as a market share gainer in 2023. Wells Fargo initiates Snowflake as overweight Wells said in its initiation of the stock that it's built to "weather the storm." Piper Sandler names Amazon a top 2023 pick Piper Sandler says it sees share gains and easing comps for the e-commerce giant. " Bank of America names Domino's a top 2023 pick The firm says Domino's is well positioned in a declining macroeconomic environment.

☆ IBM and more: CNBC's 'Halftime Report' traders answer your stock questions
▼ + stars: | 2023-01-05 | by ( Joshua Natoli | ) www.cnbc.com time to read: 1 min

On Thursday's "Ask Halftime," our traders answered questions from CNBC Pro subscribers about stocks and ETFs during this market volatility, including whether to buy, sell or hold specific names. Shannon Saccocia of SVB Private Bank shared her thesis on IBM , and why she thinks it is positioned to deliver strong results as a value tech play over the next year. Steve Weiss of Short Hills Capital explained why Moderna is a solid long-term hold. Finally, Jason Snipe of Odyssey Capital Advisors says the oil and gas trade will be positive in 2023 thanks to the economic reopening of China.

☆ Moderna signs $35 million deal with cancer drug developer CytomX
▼ + stars: | 2023-01-05 | by ( ) www.reuters.com time to read: +1 min

Jan 5 (Reuters) - Moderna Inc (MRNA.O) on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics (CTMX.O) to work on messenger RNA-based therapies for a wide range of diseases. The news comes a month after an experimental cancer vaccine from Moderna based on mRNA technology was shown to work against a type of skin cancer. The deal offers CytomX access to Moderna's mRNA technology, which has been used to develop COVID-19 vaccines, while Moderna would get access to CytomX's Probody platform, used in the development of cancer therapies targeting diseased tissues. Moderna said it will also pay tiered royalties to CytomX on global sales of any products which enter the market under the deal. The companies will work together to discover experimental therapies and Moderna will be responsible for human trials and commercial activities of products.

☆ IBM and more: CNBC's 'Halftime Report' traders answer your questions
▼ + stars: | 2023-01-05 | by ( Joshua Natoli | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIBM, Moderna and more: CNBC's 'Halftime Report' traders answer your questionsCNBC's Halftime traders Shannon Saccocia of SVB Private Bank, Steve Weiss of Short Hills Capital and Jason Snipe of Odyssey Capital Advisors answer investment-related questions from CNBC Pro subscribers. Look out for an email where you can submit your questions directly to the Halftime team.

The subvariant of omicron, named XBB.1.5, has raised concerns about another potential wave of Covid cases following the busy holiday travel season. The CDC projected Friday that about 40% of confirmed U.S. Covid cases are caused by the XBB.1.5 strain, up from 20% a week ago. There’s no indication it causes more severe illness than any other omicron virus, Dr. Barbara Mahon, director of CDC’s Coronavirus and Other Respiratory Viruses Division, told NBC News. The XBB.1.5 is a relative of the omicron XBB variant, which is a recombinant of the omicron BA.2.10.1 and BA.2.75 subvariants. Yet, only 37.5% of that age group has received the most recent omicron booster, according to the most recent CDC data.

Search resuls for: "modernă"

25 mentions found